T1	Disorder 17 27	leukopenia
N1 	Reference T1 UMLS:C0023530	leukopenia
T2	Disorder 49 63	hepatotoxicity
N2 	Reference T2 UMLS:C0348754	hepatotoxicity
N3 	Reference T2 UMLS:C0235378	hepatotoxicity
T3	Subject 74 81	carrier
T4	Pharmacological_substance 95 105	nevirapine
N1000 	Reference T4 MeSH:D019829	nevirapine
T5	Pharmacological_substance 108 118	Nevirapine
N1001 	Reference T5 MeSH:D019829	Nevirapine
T8	Disorder 196 224	human immunodeficiency virus
N4 	Reference T8 UMLS:C3854222	human immunodeficiency virus
T9	Disorder 427 437	leukopenia
N5 	Reference T9 UMLS:C0023530	leukopenia
T10	Disorder 526 542	hepatic toxicity
N6 	Reference T10 UMLS:C0348754	hepatic toxicity
T11	Disorder 573 583	leukopenia
N7 	Reference T11 UMLS:C0023530	leukopenia
T15	Subject 402 407	woman
T16	Disorder 389 392	HIV
N8 	Reference T16 UMLS:C3854222	HIV
T18	Pharmacological_substance 461 471	nevirapine
N1002 	Reference T18 MeSH:D019829	nevirapine
T19	Disorder 517 521;534 542	skin toxicity
T20	Disorder 337 354;367 374	adverse cutaneous effects
T21	Disorder 337 344;359 374	adverse hepatic effects
N9 	Reference T21 UMLS:C0413672	adverse hepatic effects
T22	Disorder 226 229	HIV
N10 	Reference T22 UMLS:C3854222	HIV
T23	Subject 240 248	patients
T26	Manner_cue 566 572	severe
T27	Disorder 70 73	HIV
N11 	Reference T27 UMLS:C3854222	HIV
